In the context of AD, the modulation of this IL-10/IL-12 axis represents a promising therapeutic strategy, particularly in mitigating neuroinflammation and microglial activation (Anwar et al., 2019, Ton et al., 2020). This evidence concerns the gene IL10 and Alzheimer disease.